Abedalrahman Maen Addassi: Edoxaban’s Journey Shows How Targeted Pharmacology and Real-World Data Converge
Abedalrahman Maen Addassi, Pharmacist, shared a post on LinkedIn:
”Innovation in Anticoagulation: Edoxaban by Daiichi Sankyo
In a world where stroke prevention and venous thromboembolism management are critical, Edoxaban (Savaysa) stands out as a once-daily oral anticoagulant that’s reshaping clinical practice.
- FDA Approval Date: January 8, 2015 A B
- Mechanism of Action: Edoxaban is a direct Factor Xa inhibitor, selectively blocking a key step in the coagulation cascade to prevent thrombus formation C.
Indications:
- Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF)
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following initial parenteral anticoagulation A B
Side Effects:
- Most common: bleeding, including gastrointestinal and intracranial hemorrhage
- Others: anemia, rash, liver enzyme elevation—requiring careful renal function monitoring, especially in patients with CrCL >95 mL/min B
How Does It Compare?
- Warfarin: Edoxaban showed non-inferior efficacy with lower rates of major bleeding in ENGAGE AF-TIMI 48 trial B
- Rivaroxaban and Apixaban: All are Factor Xa inhibitors, but edoxaban offers once-daily dosing and a favorable bleeding profile in select populations
- Dabigatran: A direct thrombin inhibitor—different mechanism, twice-daily dosing, and higher GI bleeding risk
Backed by global trials like ENGAGE AF-TIMI 48 and Hokusai-VTE, edoxaban continues to expand its footprint across more than 40 countries C.
As a recent pharmacy graduate passionate about medical information and therapeutic innovation, I find edoxaban’s journey a powerful example of how targeted pharmacology and real-world data can converge to improve patient outcomes.
Let’s connect if you’re working in anticoagulation, clinical trials, or medical affairs—I’d love to exchange insights!”
Stay updated with Hemostasis Today.
-
Oct 21, 2025, 06:59Samwel Mikaye: Polycythemia and the Risk of Blood Clots
-
Oct 21, 2025, 06:58Samuel Nweke: Interpreting D-Dimer Results
-
Oct 21, 2025, 05:20Ewa Fiorentino Rozek: APS - When “Unprovoked” Clots And Pregnancy Loss Connect
-
Oct 21, 2025, 03:503 Questions With Abigail Ajanel Gomez – Touch Haematology Future Leader 2025
-
Oct 21, 2025, 01:57Mohamed Reda: Clotting Factors — The Key Players in Blood Coagulation
-
Oct 22, 2025, 10:35Evaluating a Novel Human Fibrinogen Concentrate (BT524) for Congenital Fibrinogen Deficiency
-
Oct 22, 2025, 09:37Jurjen Krommenhoek and Colleagues Propose a Clinical Care Pathway for Major Bleeding Survivors
-
Oct 22, 2025, 09:32Ishac Nazy: Proud Moment For Our Team!
-
Oct 22, 2025, 09:16Richard Benjamin Shares Results of The ReCePI Phase III Clinical Study
-
Oct 21, 2025, 11:13Hanny Al Samkari's Commentary on Iron Deficiency Anemia in Inherited Bleeding Disorders
-
Oct 22, 2025, 08:25Johanna Nystedt: Not Every Day We Can Release a New Blood Product to Meet An Unmet Medical Need!
-
Oct 21, 2025, 06:58Arno Nierich: How Caffeine Affects Red Blood Cells and Blood Storage
-
Oct 21, 2025, 06:43Could Gene Therapy Offer Lasting Quality of Life for People with Hemophilia B?
-
Oct 21, 2025, 06:18Katerina Akassoglou Receives Zenith Fellows Award to Advance Alzheimer’s Research
-
Oct 16, 2025, 06:07ClearPlasma - A New Breakthrough in Stopping Life-Threatening Bleeds
-
Oct 22, 2025, 10:46Conversation with Ferran Nadeu – Touch Haematology Future Leader 2025
-
Oct 22, 2025, 10:32Lynn Malec - The New Director of the CCBD and Pharmacy at Children's Wisconsin
-
Oct 22, 2025, 09:41Deanna Joseph: Feeling Inspired and Deeply Grateful After Attending the 2025 HTRS SEARCH Workshop
-
Oct 22, 2025, 08:41Maryum Salim Reflects on Her Experience at the HTRS SEARCH Workshop
-
Oct 22, 2025, 08:36Emilya Huseynova to Speak at AABB 2025